Acute Hypoglycemia Decreases Myocardial Blood Flow Reserve in Patients With Type 1 Diabetes Mellitus and in Healthy Humans

Omar Rana, MBBS, MRCP; Christopher D. Byrne, PhD, FRCPath, FRCP; David Kerr, MD, FRCP; David V. Coppini, MD, FRCP; Soha Zouwail, MD, PhD, FRCPath; Roxy Senior, DM, MD, FRCP, FESC; Joe Begley, MD, FRCPath; Jeremy J. Walker, PhD; Kim Greaves, BSc, MD, FRCP

Background—Hypoglycemia is associated with increased cardiovascular mortality, but the reason for this association is poorly understood. We tested the hypothesis that the myocardial blood flow reserve (MBFR) is decreased during hypoglycemia using myocardial contrast echocardiography in patients with type 1 diabetes mellitus (DM) and in healthy control subjects.

Methods and Results—Twenty-eight volunteers with DM and 19 control subjects underwent hyperinsulinemic clamps with maintained sequential hyperinsulinemic euglycemia (plasma glucose, 90 mg/dL [5.0 mmol/L]) followed by hyperinsulinemic hypoglycemia (plasma glucose, 50 mg/dL [2.8 mmol/L]) for 60 minutes each. Low-power real-time myocardial contrast echocardiography was performed with flash impulse imaging using low-dose dipyridamole stress at baseline and during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia. In control subjects, MBFR increased during hyperinsulinemic euglycemia by 0.57 U (22%) above baseline (B coefficient, 0.57; 95% confidence interval, 0.38 to 0.75; P<0.0001) and decreased during hyperinsulinemic hypoglycemia by 0.36 U (14%) below baseline values (B coefficient, −0.36; 95% confidence interval, −0.50 to −0.23; P<0.0001). Although MBFR was lower in patients with DM at baseline by 0.37 U (14%; B coefficient, −0.37; 95% confidence interval, −0.55 to −0.19; P=0.0002) compared with control subjects at baseline, the subsequent changes in MBFR during hyperinsulinemic euglycemia and hyperinsulinemic hypoglycemia in DM patients were similar to that observed in control subjects. Finally, the presence of microvascular complications in the patients with DM was associated with a reduction in MBFR of 0.52 U (24%; B coefficient, −0.52; 95% confidence interval, −0.70 to −0.34; P<0.0001).

Conclusions—Hypoglycemia decreases MBFR in both healthy humans and patients with DM. This finding may explain the association between hypoglycemia and increased cardiovascular mortality in susceptible individuals.

Key Words: diabetes mellitus ■ echocardiography ■ hypoglycemia ■ insulin ■ regional blood flow

Several studies have shown that hypoglycemia is associated with an increase in cardiovascular mortality (CVM).1–6 This association has been demonstrated in people with and without established coronary artery disease.1–3 Importantly, patients with acute coronary syndromes appear to have worse short- and long-term outcomes if they experience hypoglycemia in the acute phase of their presentation.2–4 For example, in patients with diabetes mellitus (DM) and acute coronary syndromes, hypoglycemia within 48 hours of their admission was associated with a 2-fold increase in all-cause mortality over a 2-year follow-up.2 Similarly, Pinto et al5 showed that patients with ST-segment–elevation myocardial infarction and an admission blood glucose <4.5 mmol/L had a 3-fold increased rate of adverse outcomes (defined as 30-day mortality and myocardial infarction). Furthermore, in the same study, patients with DM had an 18-fold increased risk of adverse cardiac outcomes. Subsequently, a more recent study showed that in patients after myocardial infarction, spontaneous hypoglycemia was associated with a 2-fold increase in in-hospital mortality.4

Received September 29, 2010; accepted May 31, 2011.
From the Department of Cardiology, Poole Hospital and Bournemouth University, Poole (O.R., K.G.); Endocrinology & Metabolism Unit, Institute for Developmental Sciences, University of Southampton and Southampton University Hospitals Trust, Southampton General Hospital, Southampton (C.D.B.); Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth Hospital and Centre of Postgraduate Medical Research and Education, Bournemouth University, Dorset (D.K.); Departments of Diabetes and Endocrinology (D.V.C.) and Biochemistry (S.Z., J.B.), Poole Hospital, Poole; National Heart and Lung Institute, Imperial College, London, Royal Brompton Hospital, London, and Northwick Park Hospital, Harrow (R.S.); Centre for Population Health Sciences, University of Edinburgh, Edinburgh (J.J.W.), UK; and Department of Biochemistry, Alexandria University, Egypt (S.Z.).

The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.110.992297/-/DC1.

Correspondence to Kim Greaves, BSc, MD, FACC, FRCP, Cardiology Department, Poole Hospital NHS Foundation Trust, Longfleet Rd, Poole, BH15 2JB, UK. E-mail kim.greaves@poole.nhs.uk
© 2011 American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org

DOI: 10.1161/CIRCULATIONAHA.110.992297
Hypoglycemia has been associated with angina and, importantly, artery disease, an MBFR endothelial dysfunction. Furthermore, MBFR has been calculated as the ratio of peak MBF to resting MBF. In the absence of flow-limiting coronary artery disease, an MBFR <2.0 is indicative of underlying endothelial dysfunction. Furthermore, MBFR has been shown to be an independent predictor of CVM in diabetic and nondiabetic patients with normal stress echocardiograms and in patients after acute coronary syndromes.

We hypothesized that hypoglycemia would decrease the MBFR (measured by MCE) using a 1-step hyperinsulinemic clamp technique to induce hypoglycemia in patients with type 1 DM and in healthy control subjects.

Methods

Subjects

Twenty-eight subjects with type 1 DM (group DM) participated in the study after approval of the local research ethical committee. In addition, 19 healthy volunteers (group C) acted as control subjects. All volunteers underwent testing of MBF by MCE. Assessment of MBF was undertaken with an insulin clamp at 3 stages: at baseline, during hyperinsulinemic euglycemia (HE), and during hyperinsulinemic hypoglycemia (HH). During each stage, all volunteers underwent measurement of MBF during 2 states: at rest and after dipyridamole-induced stress.

None of the volunteers were active smokers or had a history of hypertension, coronary artery disease, or underlying lipid disorders. All volunteers had normal exercise stress echocardiograms. Within the DM group, 8 volunteers had evidence of microvascular complications (see the online-only Data Supplement). All volunteers provided written informed consent.

Hyperinsulinemic Clamps

Volunteers were admitted after an overnight fast. The overall study scheme is shown in Figure 1A and 1B. Written instructions were provided to avoid caffeine-containing products and alcohol for >12 hours. In the DM group, a standard sliding-scale insulin was begun to keep glucose levels close to 90 mg/dL (5.0 mmol/L). After a 30- to 40-minute rest period, baseline plasma glucose was determined, and the hyperinsulinemic clamp was begun. Insulin was infused at 3 mU · kg⁻¹ · min⁻¹ for 4 minutes, followed by 2 mU · kg⁻¹ · min⁻¹ for a further 3 minutes, after which the infusion rate was maintained at 1.5 mU · kg⁻¹ · min⁻¹. Hyperinsulinemic euglycemia (90 mg/dL [5.0 mmol/L]) was maintained for 60 minutes after an initial 30-minute stabilization period. Glucose levels were subsequently reduced over a 30-minute period by decreasing the 20% (wt/vol) dextrose (Baxter Healthcare, Thetford, Norfolk, UK) infusion rate, and symptomatic hypoglycemia (50 mg/dL [2.8 mmol/L]) was induced (see the online-only Data Supplement). The glucose concentrations were maintained for a further 60 minutes (HH), after which insulin infusion was terminated and normoglycemia was restored.

Myocardial Contrast Echocardiography

We performed MCE using a commercial ultrasound machine iE33 (Philips Medical Systems, Best, the Netherlands) and SonoVue (Bracco Research SA, Geneva, Switzerland) as the contrast agent as previously described. Real-time images were recorded within 3 to 4 minutes in the 3 apical views (apical 4-chamber, apical 2-chamber, and apical 3-chamber views) with low-power settings at a mechanical index of 0.1. The focus was set at the mitral valve level. SonoVue was initially started at 60 mL/h through the left antegrade cannula with the VueJect infusion syringe pump (BR-INF 100, Bracco Research, SA), which gently rotates and maintains the contrast agent in a suspension. Thereafter, the rate was set between 48 and 60 mL/h to maximize image quality with minimal attenuation. Once optimized, the machine settings were held constant throughout each participant study. Flash-impulse imaging at a high mechanical index (1.0) was performed to achieve complete myocardial bubble destruction, after which 10 end-systolic frames were recorded digitally in each apical view. After the resting images were acquired, dipyridamole was infused at 0.56 mg/kg over a 4-minute period. After an interval of 2 minutes, poststress images were recorded within 3 to 4 minutes. This entire sequence took 14 minutes (Figure 1B). The MCE studies were performed at baseline before insulin infusion and during HE and HH (Figure 1A). Continuous ECG monitoring was undertaken, and blood pressure was recorded before and after stress during each study.

Analytic Methods

Quantitative MCE analysis was performed offline with standard commercially available software, QLab version 7.0 (Q-Laboratory, Philips Medical Systems). Quantitative assessment of myocardial perfusion was performed for 10 consecutive end-systolic frames after microbubble destruction. A region of interest was placed over the
entire thickness of the myocardium, and particular care was taken to exclude high-intensity epicardial and endocardial borders by manually moving the region of interest between each frame (see Figure 2). Background-subtracted plots of peak myocardial contrast intensity (representing myocardial blood volume $A$, dB) versus pulsing intervals (representing time) were automatically constructed by QLab software to fit the monoexponential function conventional equation: $y = A \left(1 - e^{-\beta t}\right)$,14 From these plots, the slope of the replenishment curve was determined (representing myocardial blood velocity $\beta$, dB/s). The product of $A$ and $\beta$ yielded resting MBF (dB²/s) and postdipyridamole MBF (peak MBF, dB²/s), respectively (Figure I in the online-only Data Supplement).14 We calculated MBFR by the ratio of peak MBF to resting MBF.14 Furthermore, MBFR was calculated by dividing the peak MBF by the resting MBF of the same segment at each of the 3 time frames (baseline, HE, and HH). The basal segments were not included in the analysis because of contrast attenuation.22 The remaining 10 mid and apical cardiac segments were analyzed as shown in Figure 2.22 A segment was not included in the analysis if there was artifact, inadequate microbubble destruction, attenuation, or a wide variation in contrast intensity to minimize errors. The average number of analyzable segments for baseline, HE, and HH was 6 for each. All studies were reanalyzed blindly for intraobserver variability, and for interobserver agreement, 100 myocardial segments were randomly analyzed by another observer (K.G.) who was blinded to the sequence of the studies. The intraobserver and interobserver variabilities were 7.7% and 8.2%, respectively.

Venous samples were taken at baseline and every 30 minutes thereafter (7 samples in total) for determination of plasma endothelin-1 (ET-1) and epinephrine levels, as well as serum high-sensitivity C-reactive protein and insulin levels. All assays were performed in duplicate by a single observer (S.Z.) who was blinded to the hemodynamic and MCE data. Plasma ET-1 levels were measured with a quantitative sandwich enzyme immunoassay (QuantGlo ELISA, R&D Systems, Abingdon, UK) according to the manufacturer’s instructions. Intra-assay and interassay coefficients of variation were 3.4% and 8.9%, respectively, with a cross-reactivity of $<0.02$% for all human big ET1s, 9% for ET-3, and 51% for ET-2. Plasma high-sensitivity C-reactive protein was determined with a particle-enhanced immunoassay with an interassay coefficient of variation $<10$% (Roche Diagnostics, Burgess Hill, UK). Plasma epinephrine levels were measured after extraction and acetylation by competitive immunoassay (Labor Diagnostika Nord, Nordhorn, Germany). Serum insulin concentrations were measured with electrochemiluminescence immunoassay (Roche Diagnostics, Burgess Hill, UK). The assay shows minimal cross-reactivity with proinsulin or recombinant insulin analogs, and the intra-assay and interassay coefficients of variation were $<2$% and $<5$%, respectively.

**Statistical Analysis**

All data are represented as mean±SD except ET-1 and high-sensitivity C-reactive protein values, which are presented as median (interquartile range).

For MBF, $\beta$, and $A$, the influence of measurement stage, stress state, and the presence of DM was assessed via mixed-effects regression modeling (to reflect the intraclass correlation resulting from repeated measurements made on each subject). For each of these 3 outcomes, a mixed-effects model was fitted in which the main effects of stage, stress state, and DM (together with all of their possible interactions) were assessed. Modeling was performed with the MIXED procedure in SAS software (version 9.2). Interpretation of these models is described in the online-only Data Supplement.

In addition to yielding regression parameter estimates, the models were used to estimate mean values for each combination of effects (via the LSMEANS option in the MIXED procedure) and to test for selected differences in these means. With 12 effects combinations (ie, 3 stages×2 stress states×2 diabetes states [present/absent]), the maximum number of possible between-group differences was 66. It was fully recognized that formal testing of between-group differences under these conditions was justified only when there was some a priori reason to anticipate the presence of an effect of interest and
Table 1. Baseline Characteristics of Subjects

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group</th>
<th>Group</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>38.7±9</td>
<td>31.8±8</td>
<td>0.013</td>
</tr>
<tr>
<td>Men, %</td>
<td>22 (79)</td>
<td>11 (58)</td>
<td>0.13</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.7±3.5</td>
<td>24.9±2.6</td>
<td>0.39</td>
</tr>
<tr>
<td>SBP, mm Hg</td>
<td>125±13</td>
<td>115±10</td>
<td>0.007</td>
</tr>
<tr>
<td>DBP, mm Hg</td>
<td>77±7</td>
<td>73±7</td>
<td>0.05</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>78±14</td>
<td>79±16</td>
<td>0.71</td>
</tr>
<tr>
<td>Fasting glucose, mmol/L</td>
<td>10.3±3.9</td>
<td>4.9±0.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Duration of diabetes mellitus, y</td>
<td>19.2±12</td>
<td>19.8±12</td>
<td>0.40</td>
</tr>
<tr>
<td>Glycosylated hemoglobin (HbA1c), %</td>
<td>8.9±1.5</td>
<td>8.6±1.5</td>
<td>0.36</td>
</tr>
<tr>
<td>Albumin/creatinine ratio, mg·mmol⁻¹·L⁻¹</td>
<td>4.3±9.4</td>
<td>4.4±9.4</td>
<td>0.91</td>
</tr>
<tr>
<td>VPT score</td>
<td>8.0±5.6</td>
<td>8.0±5.6</td>
<td>1.00</td>
</tr>
<tr>
<td>TC, mmol/L*</td>
<td>4.8±0.9</td>
<td>4.8±0.9</td>
<td>0.03</td>
</tr>
<tr>
<td>LDL-C, mmol/L*</td>
<td>2.5±0.8</td>
<td>2.4±0.4</td>
<td>0.10</td>
</tr>
<tr>
<td>HDL-C, mmol/L*</td>
<td>1.8±0.7</td>
<td>1.5±0.3</td>
<td>0.10</td>
</tr>
<tr>
<td>TG, mmol/L†</td>
<td>1.2±0.7</td>
<td>1.3±0.7</td>
<td>0.81</td>
</tr>
</tbody>
</table>

DM, type 1 diabetes mellitus; C, control; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; VPT, vibration perception threshold; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; and TG, triglycerides. Data are presented as mean±SD.

*To convert mmol/L to mg/dL, multiply by 38.7.
†To convert mmol/L to mg/dL, multiply by 88.6.

under the strict understanding that the primary purpose of such testing was the generation of hypotheses for future research rather than the drawing of substantive inferences. For further detailed explanation, see the online-only Data Supplement.

Results

Subject Characteristics
The baseline characteristics of the 19 healthy volunteers (group C) and 28 volunteers with DM are summarized in Table 1.

Hemodynamic Data
Throughout the clamp, resting heart rate, resting systolic blood pressure, resting diastolic blood pressure, and resting rate-pressure product were similar in groups C and DM (Table I in the online-only Data Supplement).

Myocardial Contrast

Echocardiography–Derived Measurements

Myocardial Blood Volume
Mean myocardial blood volumes and 95% confidence intervals (95% CIs) at rest (Ar) and during dipyridamole-induced stress (Ad) are shown at baseline and during HE and HH in Table 2. Table 3 shows the mixed-effect regression modeling
testing the effect of stage, state, DM, and their interactions on $A_r$ and $A_d$.

There was a significant increase in $A_d$ in group C at baseline by 2.7 dB ($P<0.0001$), as shown in Table 3. In addition, there was marginal evidence that $A_d$ was decreased during HH by 1.4 dB compared with baseline ($P=0.068$). Furthermore, the presence of DM did not affect either $A_r$ or $A_d$ at the baseline stage ($P=0.25$ and $P=0.65$, respectively). However, there was a suggestion that $A_d$ was increased in group DM during HH compared with group C by 1.9 dB ($P=0.056$).

**Myocardial Blood Velocity**

Mean myocardial blood velocities and 95% CIs at rest ($\beta_r$) and during dipyridamole-induced stress ($\beta_d$) are shown at baseline and during HE and HH in Table 4. Table 5 shows the mixed effect regression modeling testing the effect of stage, state, DM and their interactions on $\beta_r$ and $\beta_d$.

There was a significant increase in $\beta_d$ in group C at baseline by 1.08 dB/s ($P<0.0001$), as shown in Table 5. During HE, $\beta_d$ was further increased in group C compared with baseline values by 0.37 dB/s ($P<0.0001$). However, during HH, $\beta_d$ declined and was not different from baseline stress values ($P=0.28$). In group DM, $\beta_d$ was significantly elevated compared with group C at baseline by 0.11 dB/s ($P=0.035$). Importantly, at baseline, $\beta_d$ was significantly decreased in group DM compared with group C by 0.27 dB/s ($P=0.005$).

In group DM, during HE and HH, a similar effect on $\beta_d$ was observed compared with group C with no significant differences between the 2 groups at each stage.

**Myocardial Blood Flow**

Mean MBFs and 95% CIs at rest (resting MBF) and during dipyridamole stress (peak MBF) are shown at baseline and during HE and HH in Table 4. Table 5 shows the mixed-effect regression modeling testing the effect of stage, state, DM and their interactions on MBF.

In group C, peak MBF was significantly increased compared with resting MBF at baseline by 26.5 dB²/s ($P<0.0001$) as shown in Table 7. During HE, peak MBF was further increased in group C above baseline peak values by 11.6 dB²/s ($P<0.0001$). However, during HH, peak MBF declined and was not significantly different from baseline peak MBF values ($P=0.20$).

The resting MBF was significantly higher in group DM compared with group C at baseline by 2.6 dB²/s ($P=0.015$). There was no significant difference in the resting MBF values between the 2 groups at HE or HH. In group DM, peak MBF was significantly decreased compared with group C at baseline by 6.0 dB²/s ($P=0.006$). In group DM, during HE and HH, a similar effect on peak MBF was observed compared with group C with no significant differences between the 2 groups at each stage.

**Myocardial Blood Flow Reserve**

We tested the effect of measurement stage, age, presence of DM, and systolic blood pressure on MBFR using regression modeling (Table 8 and Figure 3). In Table 8, the intercept of

---

**Table 4. Myocardial Blood Velocity ($\beta$) at Rest and After Dipyridamole-Induced Stress at Baseline and During Hyperinsulinemic Euglycemia and Hyperinsulinemic Hypoglycemia**

<table>
<thead>
<tr>
<th>Stage</th>
<th>DM Rest ($\beta_r$, dB/s)</th>
<th>DM Peak ($\beta_d$, dB/s)</th>
<th>C Rest ($\beta_r$, dB/s)</th>
<th>C Peak ($\beta_d$, dB/s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>1.03 (0.96–1.09)</td>
<td>1.84 (1.70–1.98)</td>
<td>0.92 (0.84–1.00)</td>
<td>2.00 (1.83–2.17)</td>
</tr>
<tr>
<td>HE</td>
<td>1.11 (1.05–1.17)</td>
<td>2.37 (2.22–2.51)</td>
<td>0.96 (0.88–1.03)</td>
<td>2.41 (2.23–2.58)</td>
</tr>
<tr>
<td>HH</td>
<td>1.18 (1.12–1.24)</td>
<td>1.85 (1.74–1.97)</td>
<td>1.04 (0.96–1.11)</td>
<td>2.03 (1.89–2.17)</td>
</tr>
</tbody>
</table>

Stage is baseline, hyperinsulinemic euglycemia (HE), or hyperinsulinemic hypoglycemia (HH). State is resting (resting blood velocity=$\beta_r$) or during dipyridamole stress (peak=$\beta_d$). Values are means (95% confidence intervals).

---

**Table 5. Mixed-Effect Regression Model Showing the Effect of Measurement Stage (at Baseline, During Hyperinsulinemic Euglycemia, and During Hyperinsulinemic Hypoglycemia), Presence of Diabetes Mellitus, and Stress State (Rest Versus After Dipyridamole-Induced Stress) on Myocardial Blood Velocity ($\beta$)**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measurement stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>0.92</td>
<td>0.84–1.00</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Euglycemia</td>
<td>0.96</td>
<td>0.88–1.03</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>1.04</td>
<td>0.96–1.11</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>State (after stress vs rest)</td>
<td>1.08</td>
<td>0.94–1.22</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Interaction (stage with state)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia and poststress</td>
<td>-0.08</td>
<td>-0.23–0.07</td>
<td>0.28</td>
</tr>
<tr>
<td>Hypoglycemia and poststress</td>
<td>-0.11</td>
<td>-0.21–0.01</td>
<td>0.035</td>
</tr>
<tr>
<td>Presence of diabetes mellitus (yes vs no)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interaction (stage with diabetes mellitus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia and diabetes mellitus present</td>
<td>0.04</td>
<td>-0.05–0.14</td>
<td>0.36</td>
</tr>
<tr>
<td>Hypoglycemia and diabetes mellitus present</td>
<td>0.03</td>
<td>-0.05–0.12</td>
<td>0.46</td>
</tr>
<tr>
<td>Interaction (state with diabetes mellitus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poststress and diabetes mellitus present</td>
<td>-0.27</td>
<td>-0.45–0.08</td>
<td>0.005</td>
</tr>
<tr>
<td>Interaction (stage with state with diabetes mellitus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia, poststress, diabetes mellitus present</td>
<td>0.07</td>
<td>-0.08–0.23</td>
<td>0.35</td>
</tr>
<tr>
<td>Hypoglycemia, poststress, diabetes mellitus present</td>
<td>-0.05</td>
<td>-0.25–0.14</td>
<td>0.58</td>
</tr>
</tbody>
</table>

CI indicates confidence interval.
the mixed model, the B coefficient, was 3.16 (95% CI, 2.47 to 3.85) with baseline used as a reference point. In group C, MBFR increased during HE by 0.57 U (2.67 ± 0.3 to 3.1 ± 0.5; P < 0.0001) (22%) above baseline and decreased during HH by 0.36 U (2.67 ± 0.3 to 2.27 ± 0.2; P < 0.0001) (14%) below baseline values. Importantly, at baseline, MBFR was significantly lower in group DM compared with group C by 0.37 U (2.67 ± 0.3 versus 2.17 ± 0.3; P = 0.0002). In group DM during HE (2.5 ± 0.5), a similar effect on MBFR was observed compared with group C; however, there was a suggestion that in group DM, there was a smaller decrease in MBFR during HH (1.9 ± 0.4), compared with the decrease in MBFR observed in group C (P = 0.05). Although there was a highly significant (P = 0.003) and independent negative effect of age on MBFR, the B coefficient (−0.01) shows that the magnitude of this effect for each year of age was small. Finally, there was no independent effect of systolic blood pressure on MBFR.

**Table 7. Mixed-Effect Regression Model Showing the Effect of Measurement Stage, Age, Presence of Diabetes Mellitus, and Stress State (Rest Versus After Dipyridamole-Induced Stress) on Myocardial Blood Flow Reserve**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Estimate</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Measurement stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>17.7</td>
<td>16.1–19.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Euglycemia</td>
<td>19.3</td>
<td>17.3–21.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypoglycemia</td>
<td>22.2</td>
<td>20.4–24.0</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>State (poststress vs rest)</td>
<td>26.5</td>
<td>23.3–29.7</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Interaction (stage with state)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia and poststress</td>
<td>11.6</td>
<td>8.9–14.4</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypoglycemia and poststress</td>
<td>−2.0</td>
<td>−5.1–1.1</td>
<td>0.20</td>
</tr>
<tr>
<td>Presence of diabetes mellitus (yes vs no)</td>
<td>2.6</td>
<td>0.5–4.7</td>
<td>0.015</td>
</tr>
<tr>
<td>Interaction (stage with diabetes mellitus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia and diabetes mellitus present</td>
<td>0.3</td>
<td>−2.1–2.6</td>
<td>0.83</td>
</tr>
<tr>
<td>Hypoglycemia and diabetes mellitus present</td>
<td>−0.4</td>
<td>−2.4–1.6</td>
<td>0.71</td>
</tr>
<tr>
<td>Interaction (stage with diabetes mellitus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poststress and diabetes mellitus present</td>
<td>−6.0</td>
<td>−10.1–−1.8</td>
<td>0.006</td>
</tr>
<tr>
<td>Interaction (stage with state with diabetes mellitus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia, poststress, diabetes mellitus present</td>
<td>−0.9</td>
<td>−4.4–2.6</td>
<td>0.60</td>
</tr>
<tr>
<td>Hypoglycemia, poststress, diabetes mellitus present</td>
<td>1.3</td>
<td>−2.7–5.3</td>
<td>0.51</td>
</tr>
</tbody>
</table>

CI indicates confidence interval.

**Table 8. Effect of Measurement Stage, Age, Presence of Diabetes Mellitus, and Systolic Blood Pressure on Myocardial Blood Flow Reserve**

<table>
<thead>
<tr>
<th>Variable</th>
<th>B Coefficient</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>3.16</td>
<td>2.47–3.85</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Measurement stage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia vs baseline</td>
<td>0.57</td>
<td>0.38–0.75</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hypoglycemia vs baseline</td>
<td>−0.36</td>
<td>−0.50–−0.23</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Age (+1 y)</td>
<td>−0.01</td>
<td>−0.02–−0.00</td>
<td>0.003</td>
</tr>
<tr>
<td>Presence of diabetes mellitus</td>
<td>−0.37</td>
<td>−0.55–−0.19</td>
<td>0.0002</td>
</tr>
<tr>
<td>Interaction (stage with diabetes mellitus)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euglycemia and diabetes mellitus present</td>
<td>−0.14</td>
<td>−0.38–−0.09</td>
<td>0.24</td>
</tr>
<tr>
<td>Hypoglycemia and diabetes mellitus present</td>
<td>0.17</td>
<td>0.00–0.35</td>
<td>0.05</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>−0.00</td>
<td>−0.01–0.00</td>
<td>0.56</td>
</tr>
</tbody>
</table>

CI indicates confidence interval.
patients with type 1 DM. Therefore, the overall effect of
cular complications is associated with a decrease in MBFR in
volume. We have also shown that the presence of microvas-
duction in myocardial blood velocity rather than blood
reduction in peak MBF during HH appeared to be due to a
increase in peak MBF and MBFR, whereas hypoglycemia led
with type 1 DM and healthy subjects. We have demonstrated
hypoglycemia (HH). ● indicates healthy control subjects; ■, type
hypoglycemia during HH is to suppress peak MBF, thereby
mitigating the vasodilatory action of hyperinsulinemia that
occurs during physiological glucose concentrations.
A significant amount of evidence has associated hypogly-
cemia with increased CVM.1–3,6,23,24 In a study including
40 069 patients, fasting hypoglycemia was independently
associated with a 3-fold increased risk in CVM after a mean
follow-up of 8 years.1 Pinto et al3 observed that after
ST-segment–elevation myocardial infarction, patients with a
Thrombolysis in Myocardial Infarction risk score >4 and
concomitant hypoglycemia had a >11-fold increased risk of
death within 30 days compared with those with normal
glucose levels. Furthermore, another study including patients
with established coronary artery disease showed that fasting
hypoglycemia was associated with a 2-fold increase in
all-cause mortality.23 A subsequent study observed a 16%
increase in the relative risk of CVM in the group receiving
insulin therapy on admission to intensive care.6 Although this
finding was unexplained, there was a 13-fold increased
prevalence of severe hypoglycemia in the patients on insulin
therapy compared with patients receiving conventional ther-
apy. More recently, another study has demonstrated that
fasting hypoglycemia was associated with a 33% increase in
3-year mortality rates in a cohort of 1854 elderly patients after
an acute myocardial infarction.24 This negative impact on
survival was more pronounced in the subgroups with DM and
those requiring coronary artery bypass grafting with a 2- and
3-fold increase in 3-year mortality rates, respectively. This
evidence suggests that hypoglycemia is associated with short-
and long-term adverse outcomes; however, the pathophysi-
ological mechanisms are still ill defined and may vary.
Over the past few decades, several anecdotal case reports
have associated hypoglycemia with episodes of angina and
myocardial infarction.25–27 Although a direct causal link has
not been established, animal studies have demonstrated that
hypoglycemia can increase myocardial infarct size by >40%.11
Furthermore, in patients with DM and coexisting coronary artery
disease, hypoglycemia was associated with a third of all episodes
of angina and corresponding ischemic ECG changes.10
The endothelium is a highly biologically active single cell
layer responsible for the release of several substances, the most
important of which are nitric oxide and ET-1.28,29 A 21–amino
acid peptide, ET-1 is the most potent vasoconstrictor but is
identified in humans with a plasma half-life of 4 to 7 min-
utes.30,31 It induces its predominant vasoconstrictive effect by
acting on receptors located on vascular smooth muscle cells and
fibroblasts. This reduces nitric oxide bioavailability by either
decreasing its production (caveolin-1–mediated inhibition of
endothelial nitric oxide synthase activity) or increasing its
degradation (via formation of oxygen radicals).32 One recent
study demonstrated that direct infusion of ET-1 into the coronary
sinus of 6 humans decreased the coronary blood flow in a
dose-related manner by up to 25%.33 In addition, ET-1 levels
have been shown to be the strongest predictor of no reflow
after primary angioplasty.34 Several disease states have been shown
to be associated with endothelial dysfunction (an imbalance be-
tween the bioavailability of nitric oxide and ET-1). Examples
include atherosclerosis, pulmonary arterial hypertension, DM,
and myocardial ischemia.39,34–36

![Figure 3. Myocardial blood flow reserve (MBFR) at baseline and
during hyperinsulinemic euglycemia (HE) and hyperinsulinemic
hypoglycemia (HH). ● indicates healthy control subjects; ■, type
1 diabetes mellitus patients (means±SD).](Image)
Acute hypoglycemia has also been shown to increase ET-1 concentrations. Wright and coworkers demonstrated that ET-1 levels in patients with type 1 DM rose by almost 70% above baseline values 1 hour after insulin-induced hypoglycemia. In our study, although baseline ET-1 levels were 2-fold higher in the DM group compared with control subjects, the effect of HH versus HE on ET-1 is uncertain. We suggest that further work is needed specifically to elucidate the effects of more prolonged periods of hypoglycemia on ET-1 expression.

It is also plausible that other effects of hypoglycemia may have a deleterious impact on MBFR besides increases in ET-1. Hypoglycemia induces a hypercoagulant state in humans via increased platelet aggregation and changes in plasma concentrations of coagulation factors. For example, it has been shown that factor VIII was increased 2-fold after 30 minutes of hypoglycemia. Hypoglycemia may also be responsible for initiating an inflammatory response. In 1 study, hypoglycemia was associated with a 3-fold increase in the neutrophil count and an elevation in neutrophil elastase, a potent proteolytic enzyme. Long-QT syndrome is well recognized as being associated with an increased risk of sudden cardiac death. More worryingly, acute hypoglycemia has been demonstrated to produce prolongation of the corrected QT interval by up to 35% in patients with type 1 DM, with values reaching >550 milliseconds. Interestingly, this change seems to be attributed predominantly to a surge in catecholamine levels and is independent of electrolyte imbalance. Finally, prolonged hypoglycemia can have a detrimental effect on cardiac metabolism because of the inability of the heart to use glucose, the preferred substrate instead of fatty acids (during acute myocardial ischemia), after exhaustion of myocardial glycogen reserves.

In light of our findings, it is plausible to suggest that hypoglycemia, by causing a decrease in MBFR, may increase the risk of CVM in susceptible individuals.

Limitations
Although dipyridamole was used 3 times in succession with our study protocol (Figure 1A and 1B), we consider that the repeated use of dipyridamole was unlikely to artifactualy influence our results (see the online-only Data Supplement). We did not calculate absolute myocardial perfusion values because all settings and infusion parameters, once optimized at the start of each patient study, were kept constant for the rest of that individual procedure. We deliberately did not randomize the sequence of HE and HH because this allowed individuals to act as their own controls, permitting constant insulin levels, contrast infusion rates, and ultrasound machine settings.

Conclusions
This study has shown that insulin-induced hypoglycemia is associated with a decrease in MBFR in healthy control subjects as a result of a reduction in peak MBF and that patients with type 1 DM behave in a similar manner. In contrast, insulin infusion at normal plasma glucose concentrations is associated with an increase in MBFR caused by an increase in peak MBF. Exploratory analyses suggest that the presence of DM and microvascular complications are independently associated with MBFR during HH. We speculate from our results that alterations in MBFR may explain the observed association between hypoglycemia and increased CVM in susceptible individuals.

Acknowledgments
Christopher Byrne would like to acknowledge the support of National Institute for Health Research.

Sources of Funding
This study was funded by the Cardiac Research Fund, Poole Hospital NHS Trust, and the Cardiac Research Fund, Institute of Postgraduate Medical Education and Research, Northwick Park Hospital, Harrow, UK. LREC registration No. 08/H0201/22.

Disclosures
None.

References


15. Vogel R, Indermuehle A, Reinhardt J, Meier P, Siegrist PT, Namdar M, Kaufmann PA, Seiler C. The quantification of absolute myocardial per-

CLINICAL PERSPECTIVE
Hypoglycemia is a common problem that occurs in almost 20% of patients receiving intensive insulin therapy in hospital. Several studies have recently shown that hypoglycemia is associated with an increase in cardiovascular mortality. This association has been demonstrated in people with and without established coronary artery disease. Importantly, patients with acute coronary syndromes appear to have worse short- and long-term outcomes if they experience hypoglycemia in the acute phase of their presentation. The pathophysiological mechanism responsible for this association is not known. This present study examined the effects of hypoglycemia on myocardial blood flow (MBF) reserve using myocardial contrast echocardiography in subjects with type 1 diabetes mellitus and healthy control subjects. With the use of a 1-step hyperinsulinemic clamp technique, insulin-induced hypoglycemia decreased the MBF reserve in both patients with type 1 diabetes mellitus and healthy subjects. Furthermore, during hyperinsulinemic euglycemia, insulin induced a marked increase in peak MBF and MBF reserve, whereas hypoglycemia led to an increase in resting MBF and a decrease in peak MBF, thereby decreasing the MBF reserve overall. This effect was observed in both healthy individuals and patients with type 1 diabetes mellitus. We speculate from our results that alterations in MBF reserve may provide an explanation for the observed association between hypoglycemia and increased cardiovascular mortality in susceptible individuals.
Acute Hypoglycemia Decreases Myocardial Blood Flow Reserve in Patients With Type 1 Diabetes Mellitus and in Healthy Humans

Omar Rana, Christopher D. Byrne, David Kerr, David V. Coppini, Soha Zouwail, Roxy Senior, Joe Begley, Jeremy J. Walker and Kim Greaves

_Circulation_. published online September 12, 2011;
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2011/09/11/CIRCULATIONAHA.110.992297

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2011/09/13/CIRCULATIONAHA.110.992297.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/
Supplemental Material
**Methods**

**Subjects**

Microvascular complications (retinopathy, neuropathy and nephropathy) were defined by the presence of pre- or proliferative diabetic retinopathy, on clinical examination and a vibration perception threshold score of >12 (measured on the Great Hallux using a Bio-thesiometer [Biomedical Instrument, Newbury, Ohio, USA]), and an albumin/creatinine ratio of >2.5 mg.mmol\(^{-1}\).L\(^{-1}\) for men and >3.5 mg.mmol\(^{-1}\).L\(^{-1}\) for women. Five patients with type 1 DM and microvascular complications who were taking an angiotensin converting enzyme inhibitor and a statin were instructed not to take their medications 48 hours prior to the study day to rule out any acute effects of medication on myocardial perfusion.

**Hyperinsulinemic Clamps**

Two anterograde and one retrograde cannulae were sited after application of a local anaesthetic cream (Ametop gel 4.0% w/w, Smith and Nephew, UK) to minimise discomfort. The anterograde cannulae were inserted into the antecubital fossa on either side. The right anterograde cannula was used for insulin (Actrapid; Novo Nordisk, Copenhagen, Denmark) and 20% dextrose infusions. A retrograde cannula was inserted into the dorsum of the right hand and was kept patent with a slow infusion of 0.9% (w/v) saline to which 1000 units of heparin were added. This hand was placed in a heated box (55-60°C) to obtain arterialized samples. All studies were performed in a quiet and comfortable room (22-25°C) with the volunteers resting on a couch in a semi-reclined position. Arterialised glucose sampling was performed every 3-5 minutes and the 20% dextrose infusion was adjusted accordingly. Plasma glucose was determined using a glucose oxidase method (YSI 2300 STAT Plus, Yellow Springs, OH, USA).
Volunteers were asked to report any symptoms that could be attributed to hypoglycemia which included general symptoms (dry mouth, headache, and weakness), autonomic symptoms (palpitations, trembling, tingling, sweating and feeling hungry) and neuroglycopenic symptoms (poor concentration, dizziness and blurred vision). All volunteers were provided with meals and observed for 1-hour at the end of which plasma glucose was rechecked before allowing them home.

**Plasma glucose measurements**

The inter-assay coefficient of variation (CV) was <2% while the calibration of the analyzer was checked at 30-minute intervals with a glucose standard (10 mmol.L⁻¹). Volunteers were not informed of their glucose levels during the study.

**Potential additional limitations**

Although dipyridamole was used three times in succession with our study protocol (Figure 1a and b), we consider that the repeated use of dipyridamole was unlikely to artefactually influence our results. Dipyridamole has a short half-life of 8-12 minutes and the time period between each dipyridamole infusion in our study was 76 minutes. Furthermore, dipyridamole-induced changes in left ventricular ejection fraction, end-systolic volume, heart rate and diastolic blood pressure have previously been shown to return to baseline after a 60-minute period using a much higher-dose (0.76 mg.kg⁻¹) protocol.⁶

Finally, the effects of administering dipyridamole three times in succession was tested in a healthy individual over the same time-course and there was no change in MBF, MBFR or other hemodynamic parameters. We did not calculate absolute myocardial perfusion values. This was because all settings and infusion parameters,
once optimised at the start of each patient study, were kept constant for the rest of that individual procedure. Furthermore, we achieved homogenous opacification of the left ventricular blood pool and the signal intensity received was consistently between 34-36 dB. Calculation of absolute myocardial blood flows to take into account regional blood flow variations that occur within individuals would have introduced an additional potential source of error.

**Explanation of terms used in Tables 2b, 3b and 4b in the main manuscript**

Tables 2b, 3b and 4b in the main text of the paper present parameter estimates from mixed effects regression models in which the outcome of interest (respectively: myocardial blood volume, myocardial blood velocity and myocardial blood flow) is predicted by the main effects of

i. measurement stage (baseline, during hyperinsulinemic euglycemia and during hyperinsulinemic hypoglycemia)

ii. stress state (at rest and post dipyridamole-induced stress)

iii. diabetes status (controls vs. patients with diabetes)

and by all of their possible interactions: (i) with (ii); (i) with (iii); (ii) with (iii); and the single three-way interaction (i) with (ii) with (iii). Models were fitted using the MIXED procedure in SAS software version 9.2. Interpretation of the results presented in these Tables is now described.

MEASUREMENT STAGE is the estimated mean value of the outcome for control subjects, in the rest state, observed at each of the three stages (because models were fitted with the intercept suppressed). These values are identical to those given in the
‘Rest’ sub-column of the C (Controls) column in the corresponding table of means in the main text.

STATE is the estimated effect of the stress treatment on the outcome for control subjects, at the baseline stage.

INTERACTION (STAGE with STATE) estimates the extent to which the effect of the stress treatment in controls at, respectively, the euglycaemic and hypoglycemic stages varies relative to that observed at the baseline stage.

PRESENCE OF DIABETES estimates the difference in the outcome at the baseline stage, in the resting state, between control subjects and those with diabetes.

INTERACTION (STAGE WITH DIABETES) estimates the extent to which the effect of measurement stage (that is, the change in resting values of the outcome at the euglycemic and hypoglycemic stages relative to the value observed at baseline) differs between control subjects and those with diabetes.

INTERACTION (STATE WITH DIABETES) estimates the extent to which the effect of the stress treatment, at the baseline stage, differs between controls and those with diabetes.

INTERACTION (STAGE with STATE with DIABETES) estimates the additional influence on the outcome of the joint presence of all main and two-way interaction effects. This may be illustrated with reference to Table 2b, from which the predicted absolute value of myocardial blood volume under euglycemia, post-stress, in subjects with diabetes is given by:-

\[ 20.4 \text{ (main effect of euglycemic stage)} + 2.7 \text{ (main effect of stress)} + 0.7 \text{ (main effect of diabetes)} + \]
0.7 (euglycemia / stress interaction) + 
-0.9 (euglycemia / diabetes interaction) + 
-0.4 (stress / diabetes interaction) = 23.2

However, the three-way interaction term indicates that the estimated value of the outcome is 0.5 of a unit lower than that which would be predicted on the above basis (though the interaction is not statistically significant). That is, there is an additional effect arising from the joint presence of the euglycemia stage, the stress state and diabetes.
References


Table 1.

Pulse rate, systolic blood pressure, diastolic blood pressure and rate pressure product at rest and after dipyridamole-induced stress during the hyperinsulinemic clamp.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>Hyperinsulinemic Euglycemia (HE)</th>
<th>Hyperinsulinemic Hypoglycemia (HH)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C</td>
<td>DM</td>
<td>C</td>
</tr>
<tr>
<td><strong>Pulse</strong>&lt;sub&gt;r&lt;/sub&gt; b.min&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>63±9</td>
<td>68±9</td>
<td>66±8</td>
</tr>
<tr>
<td><strong>Pulse</strong>&lt;sub&gt;d&lt;/sub&gt; b.min&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>90±11</td>
<td>92±14</td>
<td>93±14</td>
</tr>
<tr>
<td><strong>SBP</strong>&lt;sub&gt;r&lt;/sub&gt; mmHg</td>
<td>121±14</td>
<td>123±16</td>
<td>124±13</td>
</tr>
<tr>
<td><strong>SBP</strong>&lt;sub&gt;d&lt;/sub&gt; mmHg</td>
<td>125±15</td>
<td>127±18</td>
<td>125±11</td>
</tr>
<tr>
<td><strong>DBP</strong>&lt;sub&gt;r&lt;/sub&gt; mmHg</td>
<td>79±12</td>
<td>73±12</td>
<td>78±9</td>
</tr>
<tr>
<td><strong>DBP</strong>&lt;sub&gt;d&lt;/sub&gt; mmHg</td>
<td>72±9</td>
<td>72±10</td>
<td>71±9</td>
</tr>
<tr>
<td><strong>RPP</strong>&lt;sub&gt;r&lt;/sub&gt; b.min&lt;sup&gt;-1&lt;/sup&gt;.mmHg</td>
<td>7739±1533</td>
<td>8394±1839</td>
<td>8163±1448</td>
</tr>
<tr>
<td><strong>RPP</strong>&lt;sub&gt;d&lt;/sub&gt; b.min&lt;sup&gt;-1&lt;/sup&gt;.mmHg</td>
<td>11375±2399</td>
<td>11705±2399</td>
<td>11533±1839</td>
</tr>
</tbody>
</table>

Pulse rate, systolic blood pressure, diastolic blood pressure and rate pressure product are presented as mean±SD.

C=Healthy controls, DM=group with diabetes mellitus, Pulse<sub>r</sub>=resting pulse, Pulse<sub>d</sub>=post-dipyridamole pulse, SBP<sub>r</sub>=resting systolic blood pressure, SBP<sub>d</sub>=post-dipyridamole systolic blood pressure, DBP<sub>r</sub>=resting diastolic blood pressure, DBP<sub>d</sub>=post-dipyridamole diastolic blood pressure, RPP<sub>r</sub>=resting rate pressure product, RPP<sub>d</sub>=post-dipyridamole rate pressure product.
Table 2:

Effect of measurement stage and presence of microvascular complications on myocardial blood flow reserve (MBFR) in subjects with diabetes.

<table>
<thead>
<tr>
<th>variable</th>
<th>B coefficient</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>INTERCEPT</td>
<td>2.24</td>
<td>2.15 to 2.34</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>MEASUREMENT STAGE:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>euglycaemia vs. baseline</td>
<td>0.47</td>
<td>0.30 to 0.65</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>hypoglycaemia vs. baseline</td>
<td>-0.16</td>
<td>-0.30 to -0.02</td>
<td>0.023</td>
</tr>
<tr>
<td>PRESENCE OF COMPLICATIONS</td>
<td>-0.52</td>
<td>-0.70 to -0.34</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td>INTERACTION (STAGE with COMPLICATIONS):</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>euglycaemia and complications present</td>
<td>-0.17</td>
<td>-0.50 to 0.16</td>
<td>0.30</td>
</tr>
<tr>
<td>hypoglycaemia and complications present</td>
<td>-0.11</td>
<td>-0.36 to 0.15</td>
<td>0.40</td>
</tr>
</tbody>
</table>
Table 3.

Endothelin-1, hs-CRP, epinephrine, and insulin concentrations during the hyperinsulinemic clamp.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Baseline</th>
<th>Hyperinsulinemic Euglycemia</th>
<th>Hyperinsulinemic Hypoglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group</td>
<td>0 mins</td>
<td>30 mins</td>
</tr>
<tr>
<td>ET-1 pg.ml⁻¹</td>
<td>C</td>
<td>0.19(1.0)</td>
<td>0.0(0.7)</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>1.44(0.5)</td>
<td>1.30(0.5)</td>
</tr>
<tr>
<td>hs-CRP mg.L⁻¹</td>
<td>C</td>
<td>0.64(0.7)</td>
<td>0.60(0.6)</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>1.17(1.9)</td>
<td>0.82(1.9)</td>
</tr>
<tr>
<td>Epinephrine pg.ml⁻¹</td>
<td>C</td>
<td>76.3±77</td>
<td>77.7±79</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>62.2±44.2</td>
<td>98.3±124.4</td>
</tr>
<tr>
<td>Insulin pmol.L⁻¹</td>
<td>C</td>
<td>43±23</td>
<td>741±180</td>
</tr>
<tr>
<td></td>
<td>DM</td>
<td>208.3±207</td>
<td>736.0±227.4</td>
</tr>
</tbody>
</table>

Values are presented as median(interquartile range) for ET-1 and hs-CRP. Values are presented as mean±SD for epinephrine and insulin.
C=healthy controls, DM=group with diabetes mellitus, ET-1=endothelin-1, hs-CRP= high sensitivity CRP, Epinephrine=epinephrine.
Figure 1. Measurement of Myocardial Blood Flow Reserve using Flash Impulse Imaging.

\[ \text{MBF}_{\text{rest}} = A \times \beta_{\text{rest}} \]
\[ \text{MBF}_{\text{peak}} = A \times \beta_{\text{peak}} \]
\[ \text{MBFR} = \frac{\text{MBF}_{\text{peak}}}{\text{MBF}_{\text{rest}}} \]

A=myocardial blood volume, \( \beta_{\text{rest}} \)=myocardial blood velocity at rest, \( \beta_{\text{peak}} \)=myocardial blood velocity at peak, \( \text{MBF}_{\text{rest}} \)=myocardial blood flow at rest, \( \text{MBF}_{\text{peak}} \)=myocardial blood flow at peak, \( \text{MBFR} \)=myocardial blood flow reserve.